EXEL Exelixis, Inc.

$56.12▼ -2.28% Healthcare Other
After hours $56.12▲ +0.00% Sep 11, 7:30 PM ET
Volume 2.92M Avg Volume (10D) 2.03M
Key Metrics & Fundamentals
Market Cap
$13.91B
P/E Ratio
17.6
Div Yield
–%
52W Range
33.76 - 59.72
% vs 50 MA
1.50%
% vs 200 MA
17.03%
RSI-14
51.1
MACD Histogram
+0.1300
Beta (1Y vs SPY)
0.58
Free Cash Flow
$298.43M
Gross Rev
$628.69M
Gross Profit
$608.03M
EBITDA
$255.40M
COGS
$20.66M
Operating Exp
$359.62M
Operating Income
$248.41M
EBIT
$248.41M
Pretax Income
$262.68M
Net Income
$212.05M
EPS (Diluted)
0.82
Price & Volume History
Loading chart…
Recent News
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
Stocktwits · Sep 11, 2026 8:19 PM
Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay
Investor's Business Daily · Sep 11, 2026 8:18 PM
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · Sep 11, 2026 7:54 PM
Sector Update: Healthcare Stocks Ease in Afternoon Trading
MT Newswires · Sep 11, 2026 5:47 PM
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months
InvestorsHub · Sep 11, 2026 1:30 PM
Sector Update: Healthcare Stocks Flat to Higher Premarket Friday
MT Newswires · Sep 11, 2026 1:16 PM
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Inflation Data Release
MT Newswires · Sep 11, 2026 1:14 PM
Sector Update: Healthcare
MT Newswires · Sep 11, 2026 1:02 PM
Exelixis Says FDA Extended Review Period for Colorectal Cancer Drug
MT Newswires · Sep 11, 2026 11:36 AM
Adagene Receives Milestone Payment From Exelixis
MT Newswires · Sep 9, 2026 1:42 PM
Financial Overview - Income Statement Quarterly

See EXEL's money flow as a full page

Social Sentiment
Avg +0.60 · 2 posts
DiscussionMy Portfolio vs S&P 500 (Last 3 Weeks)
r/stocks · Jul 10, 2026
The author highlights Exelixis' performance within their portfolio.
positive +0.60
NewsTradebeen running a nightly insider buy screen since february
r/stocks · Jun 1, 2026
The author highlights an executive's purchase coinciding with positive news, indicating potential interest.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙